Home Newsfeeds Apple Exec Says Digital Advertising And Gaming Are Areas Where Co. Sees Some Softness

News

Apple Exec Says Digital Advertising And Gaming Are Areas Where Co. Sees Some Softness

-Reuters

byBenzinga Newsdesk

October 27, 2022

1 minute read

-Reuters

FDA
News

Molecular Partners Announces Publication In Nature Biotechnology Detailing Design And Mechanism Of Ensovibep DARPin Antiviral For SARS-CoV-2

By Benzinga Newsdesk

July 21, 11:30 AM

Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication of key

MOLN

News

Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims And Supporting Scientific Innovation

By Happy Mohamed

May 18, 11:46 AM

Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent® (alirocumab) TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

AMGN

Kewaunee Scientific Q2 EPS $(0.09) Up From $(1.11) YoY, Sales $54.56M Up From $39.03M YoY

By Benzinga Newsdesk

December 8, 3:15 AM

Kewaunee Scientific (NASDAQ:KEQU) reported quarterly losses of $(0.09) per share. This is a 91.89 percent increase over losses of $(1.11) per share from the same period last year. The company reported $54.56 million in

KEQU

Kemper Q2 EPS $(0.62) Beats $(0.67) Estimate, Sales $1.43B Beat $1.36B Estimate

By Benzinga Newsdesk

August 1, 4:17 PM

Kemper (NYSE:KMPR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.67) by 7.46 percent. This is a 59.74 percent increase over losses of $(1.54) per share from the same

KMPR

Apple Exec Says Digital Advertising And Gaming Are Areas Where Co. Sees Some Softness

Related Posts

Molecular Partners Announces Publication In Nature Biotechnology Detailing Design And Mechanism Of Ensovibep DARPin Antiviral For SARS-CoV-2

Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims And Supporting Scientific Innovation

Kewaunee Scientific Q2 EPS $(0.09) Up From $(1.11) YoY, Sales $54.56M Up From $39.03M YoY

Kemper Q2 EPS $(0.62) Beats $(0.67) Estimate, Sales $1.43B Beat $1.36B Estimate